MAP2K7 and melanoma: Collectively, these results indicate that CD47 upregulation may be an important mechanism that stifles the anti-melanoma immune response initially activated by BARF/MEK inhibitors, and suggest that the combination of CD47 blockade and BRAF/MEK inhibitors simultaneously or sequentially may be a promising approach to improve their therapeutic efficacy.